Could an immune checkpoint drug slow Alzheimer's? early trial begins

NCT ID NCT05551741

Completed Disease control Sponsor: Immunobrain Checkpoint Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This first-in-human study tested a new drug called IBC-Ab002 in 40 people with early Alzheimer's disease. The drug is an antibody that targets PD-L1, a protein involved in immune regulation. The main goal was to check safety and how the drug moves through the body, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBC-Ab002 (an anti-PD-L1 antibody)
What this could lead to: If safe and effective, this could point toward a new way to treat Alzheimer's by targeting the immune system.
What could go wrong: This is a very early Phase 1 trial with only 40 participants, focused on safety. It is too small and early to know if the drug works, and it may fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

Barzilai Medical Center

Ashkelon, Israel
Brain Research Center

Amsterdam, Netherlands
Dementia Research Centre, National Hospital for Neurology and Neurosurgery

London, United Kingdom
King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN)

London, SE5 8AF, United Kingdom
RICE - Research Institute for the Care of Older People

Bath, BA1 3NG, United Kingdom
Rabin Medical Center

Petah Tikva, Israel
Sheba Medical Center

Ramat Gan, Israel
Sheffield teaching Hospitals NHS Trust

Sheffield, United Kingdom
Tel-Aviv Sourasky Medical Center

Tel Aviv, Israel
University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.